Key Takeaways From the 340B Winter Coalition Conference

SPONSORED CONTENT

With new contract pharmacy restrictions recently announced, and more expected to come in the near future, ensuring compliance is more important than ever in the world of 340B. Here are a few takeaways from last week’s 340B Coalition winter conference in San Diego to help you and your 340B program prepare for the changes ahead.

More Restrictions

Drug manufacturers are getting increasingly restrictive regarding 340B pricing for contract pharmacy relationships. In just the past few days, Pfizer, GSK and Novartis have announced new restrictions, with GSK’s restrictions applying to all covered entities.  Most of these companies are now only going to allow the use of 340B discounts in the contract pharmacy setting at the covered entity’s in-house retail pharmacy.  The only exception is if the covered entity does not have an in-house outpatient pharmacy, they may designate one contract pharmacy location.  In some of these instances, covered entities must also:

Read More »

The Top 5 Marketing Tips for Building Your Patient Base

digital hands of doctor holding heart symbol

SPONSORED CONTENT

Saving people’s lives.
Eliminating the stigma surrounding a host of physical and mental health conditions.
Advocating for the health equity of underserved populations.
Executing targeted marketing campaigns.

One of these initiatives indeed feels less service-oriented than the others. But once you kick all its associated buzzwords to the curb, marketing is crucial to a covered entity’s ability to fulfill its vision.

Whether it’s because they’re too busy fighting fires, feel like they don’t have the financial resources, or believe they lack the expertise to get the word out about their services successfully, covered entities often shy away from strategic marketing plans. Unfortunately, doing so can keep them from attracting and retaining patients and, as a result, threaten the sustainability of their missions.

Read on as Avita Care Solution’s Chief Marketing Officer Liz Eckert and Chief Advocacy Officer Glen Pietrandoni explain why covered entities must thoughtfully promote themselves to patients in an

Read More »

AHF: Addressing Syphilis Disparities in Franklin County, OH

Aids Healthcare Foundation logo

SPONSORED CONTENT

In 1999, the Centers for Disease Control and Prevention (CDC) launched the National Campaign to Eliminate Syphilis from the United States. The CDC updated its ambitious plan in 2006 and aimed to reduce rates of primary and secondary syphilis to less than 2.2 cases per 100,000 population, congenital syphilis to less than 3.9 cases per 100,000, and the racial disparity between rates of syphilis among Black and White individuals to less than 3:1. Despite having moderate success at the turn of the century, the US is experiencing a drastic resurgence of syphilis. In 2021, the CDC reported 171,074 total cases of syphilis nationally, a 68.4% increase from 2017. Worse, there has been a sharp increase in the number of babies born with syphilis; cases of congenital syphilis rose 184.5% to 2,677 cases between 2017 and 2021.

Like other sexually transmitted infections (STIs), syphilis disparities remain with regards to

Read More »

Four Best Practices for Running Mock Audits

Estefani Ruiz headshot

SPONSORED CONTENT

With new leadership in Congress, the drumbeat for greater scrutiny of 340B will grow. To date, news outlets from The New York Times to The Wall Street Journal have quoted former government officials and pundits who’ve called for more oversight of the 340B program.  It is not just former government officials that are raising concerns, leading lawmakers from both parties are calling on 340B providers to be more transparent and ensure that they are being good stewards of the program.

Regardless of the amount and kind of attention channeled toward the 340B program, it’s always right (and a best practice) for 340B executives and managers to be meticulous. Mock audits are one way for covered entities to closely watch over their 340B program activities. These rehearsals can help program managers, staff, and healthcare employees ensure compliance and pass an audit by the

Read More »

How to Make the Most Out of the 340B Coalition Conference

Headed to the 340B Coalition Winter Conference? Here’s how to get the most bang for your buck and walk away with ideas and contacts that will impact your mission. (155)

SPONSORED CONTENT

It’s that time again: The 340B Coalition Winter Conference, known as the can’t-miss gathering of covered entities, health care providers, pharmacy and pharmacy service providers, drug manufacturers, government agencies, and other organizations dedicated to driving health equity for underserved populations via the 340B drug discount program, is just around the corner.

Over the course of three days, the event draws thousands of industry insiders, features a full program of educational, networking, and demo sessions, and showcases approximately 70 exhibitors. But with so much on the agenda—during a critical year for insights and collaboration into the changing 340B world—how can attendees get the most bang for their collective bucks?

Find out below as Avita Care Solutions leaders (and veteran 340B Coalition Conference-goers) Michael Yount and Lee Horner weigh in with tips on using the event to find thought leaders and make lasting partnerships. And don’t

Read More »

Verity Presents: 340B Outlook from Capitol Hill and the States

SPONSORED CONTENT

Will you be attending the 340B Winter Coalition Conference in San Diego? Start your week with the latest developments in the 340B program. This year, Verity Solutions will be hosting a panel discussion on Monday morning with some of the most respected long-term experts on the 340B program, including Ted Slafsky, Publisher & CEO of 340B Report and Bill von Oehsen, Principal of Powers Law. Join us for an up-to-the-minute report on hot button topics related to the legislative, legal and regulatory aspects of the 340B program.   Among the matters to be covered:

  • The latest developments in the contract pharmacy battle and what to expect next in the courts
  • An update on 340B legislative efforts in Washington, D.C. and the states including:
    • Efforts to address contract pharmacy impasse
    • Hospital transparency and good stewardship
    • Potential for Congressional hearings
    • Update on
Read More »

RxStrategies’ Launches “340B Insider Podcast” Series

In the episode “340B Insights: The Current State of the 340B Program,” RxStrategies’ Jonathan Ghenn and Rhodie Smith connect with Ted Slafsky, Publisher and CEO of the 340B Report to share information on what’s important to Covered Entities and pharmacy professionals who manage a 340B Program and provide the best care to those they serve.

About our guest, Ted Slafsky:
Publisher and Chief Executive Officer of 340B Report, Ted is a long-time healthcare thought leader and journalist. He is the Founder & Principal of Wexford Solutions LLC, has three decades of experience in 340B and journalism.

Read More »

Contract Pharmacies: An Integral 340B Component for 30 Years

SPONSORED CONTENT

This past November, the 340B program celebrated its 30th anniversary—a huge milestone and a reason to rejoice and reflect. We are dismayed, however, that certain drug manufacturers are trying to revise the 340B program’s past and reimagine its future. More than 20 drug manufacturers have unilaterally and unlawfully placed restrictions on contract pharmacy arrangements which have diminished the value of the 340B programs for communities in need. [1] However, it is vital to note that, in the last thirty years, the need for outpatient drugs to treat patients has grown exponentially, as has the price of drugs, making the 340B program more crucial than ever for safety net providers and their patients.

Most of us know that Congress passed the 340B statute in 1992 to enable covered entities “to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.”  But did you know that, when Congress was drafting the

Read More »

What’s the Secret to 340B and Specialty Pharmacy Provider and Patient Engagement?

SPONSORED CONTENT

The rise in digital technologies in the healthcare sector during the COVID-19 pandemic has resulted in some interesting trends in medical communication as we move closer to a post-pandemic world.

During the pandemic, patients became more engaged with medical communication than ever. They went from attending doctor’s visits in-person to making telehealth appointments. In addition, due to forced shutdowns, even the less tech-savvy patients learned how to navigate the internet in new ways to find information and stay connected with their healthcare providers (HCPs).

In addition to using digital mediums to communicate with their care teams, patients turned to the internet to learn more about the virus. They became comfortable performing research rather than waiting to hear what their doctor had to say, and they gained trust in the medical professionals who were providing them with frequent updates on the state of the virus.

So, the last three years have had a significant impact on the ways medical communication is

Read More »

In Wake of 340B Contract Pharmacy Restrictions, Biosimilars Deserve Consideration

SPONSORED CONTENT

Recent surveys confirm what those of you reading this know painfully well: Hospital and clinic pharmacies are struggling from the restrictions drug manufacturers are placing on 340B pricing at contract pharmacy sites. As the 340B world awaits another batch of court rulings and hopes for the best, the exclusions are harming patients’ ability to access vital medications and safety net services and delivering a serious blow to hospital and other 340B covered entity finances.

Healthcare providers can’t wait around and count on help from the courts, Congress, or the Biden administration. They need options, now, to restore their margins and ensure they can continue to serve their most vulnerable patients.

At The Craneware Group, we’ve been writing about ways covered entities can regain ground lost to the drug manufacturers and their unlawful actions. We’ve also been evaluating the utilization of biosimilars. By closely examining the 19 manufacturers restricting 340B pricing

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live